<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-21T02:51:41Z</responseDate><request verb="GetRecord" identifier="oai:macsphere.mcmaster.ca:11375/12658" metadataPrefix="dim">https://prod-ms-be.lib.mcmaster.ca/server/oai/request</request><GetRecord><record><header><identifier>oai:macsphere.mcmaster.ca:11375/12658</identifier><datestamp>2026-09-24T07:23:47Z</datestamp><setSpec>com_11375_271</setSpec><setSpec>col_11375_272</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor" lang="en_US">Devereaux, PJ</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="advisor" lang="en_US">Lamy, André</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="advisor" lang="en_US">Guyatt, Gordon</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author" lang="en_US">Lurati, Buse AL Giovanna</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="department" lang="en_US">Clinical Health Sciences (Health Research Methodology)</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2014-06-18T17:00:18Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2014-06-18T17:00:18Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="created" lang="en_US">2012-09-27</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued" lang="en_US">2012-10</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other" lang="en_US">opendissertations/7525</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other" lang="en_US">8587</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other" lang="en_US">3354342</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">http://hdl.handle.net/11375/12658</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://doi.org/10.71548/9217</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en_US">&lt;p>Introduction: Globally, more than 200 million patients undergo major non-cardiac surgery each year and more than 10 million patients will be exposed to postoperative myocardial ischemia, a condition strongly associated with 30-day mortality. The majority of these events go undetected without postoperative Troponin screening. Methods: We conducted a model-based cost-consequence analysis comparing a postoperative Troponin T screening vs. standard care in patients undergoing noncardiac surgery. In a first model, we evaluated the incremental number of detected perioperative myocardial infarctions and the incremental costs. A second model assessed the effect of the screening and consequent treatment on 1-year survival and the related cost. Model inputs based on the Vascular events In Non-cardiac Surgery patIents cOhort evaluatioN (VISION) Study, a large international cohort. We run probability sensitivity analyses with 5,000 iterations. We conducted extensive sensitivity analyses.&lt;/p> &lt;p>Results: The cost to avoid missing an event amounted to CAD$ 5,184 for PMI and CAD$ 2,983 for isolated Troponin T. The cost-effectiveness of the postoperative Troponin screening was higher in patients’ subgroups at higher risk for PMI, e.g. patients undergoing urgent surgery. The incremental costs at 1 year of a postoperative PMI screening by 4 Troponin T measurements were CAD$ 169.20 per screened patient. The cost to prevent a death at 1 year amounted to CAD$ 96,314; however, there was relevant model uncertainty associated with the efficacy of the treatment in the 1-year model.&lt;/p> &lt;p>Conclusion: Based on the estimated incremental cost per health gain, the implementation of a postoperative Troponin T screening after noncardiac surgery seems appealing, in particular in patients at high risk for perioperative myocardial infarction. However, decision-makers will have to consider it in terms of opportunity costs, i.e. in relation to the cost-effectiveness of other potential programs within the broader health care context.&lt;/p></dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degree" lang="en_US">Master of Science (MSc)</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">economic evaluation; cost-consequence analysis; troponin T; noncardiac surgery; screening</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Anesthesiology</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Cardiology</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Clinical Epidemiology</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Health Services Research</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Surgery</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Anesthesiology</dim:field>
   <dim:field mdschema="dc" element="title" lang="en_US">MODEL-BASED COST-CONSEQUENCE ANALYSIS OF POSTOPERATIVE TROPONIN T SCREENING IN PATIENTS UNDERGOING NONCARDIAC SURGERY</dim:field>
   <dim:field mdschema="dc" element="type" lang="en_US">thesis</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
</dim:dim></metadata></record></GetRecord></OAI-PMH>